In the present study, using a classic immune-inflammation stimulator LPS during the second trimester of fetal development, we found that persistent NF-κB activation can be programed during the fetal development by inflammatory challenge, and blocking NF-κB activation by PDTC could prevent hypertension development in offspring of prenatal inflammatory stimulation. This evidence concerns the gene NFKB1 and hypertensive disorder.